8-K: Arbutus Wins Key Ruling in Moderna Patent Suit

A U.S. District Court ruled that Arbutus's patent infringement claims against Moderna for most COVID-19 vaccine doses can proceed in district court, while limiting claims under the doctrine of equivalents.

Summary

• The U.S. District Court for the District of Delaware issued a memorandum and order in the patent infringement litigation between Arbutus Biopharma Corporation (and Genevant Sciences GmbH) and Moderna Inc.
• The court largely rejected Moderna's defense under 28 U.S.C. § 1498(a) for the majority of its COVID-19 vaccine doses, allowing Arbutus's claims for these doses to proceed in District Court.
• However, the court granted Moderna's defense under Section 1498(a) for vaccine doses that went directly to U.S. Government employees, channeling these specific direct infringement claims to the Court of Federal Claims.
• The court ruled that prosecution history estoppel bars Arbutus from asserting infringement claims under the doctrine of equivalents for its Molar Ratio Patents (U.S. Patent Nos. 8,492,359; 9,364,435; and 11,141,378), meaning Arbutus must prove literal infringement for these.
• Motions for summary judgment regarding the indefiniteness of Arbutus's '651 Patent (encapsulation efficiency) and Molar Ratio Patents were denied, indicating that factual disputes require a jury to decide their validity.
• The court excluded expert testimony related to the Section 1498(a) defense, finding statutory interpretation did not require it, but allowed Dr. Prudhomme's indefiniteness opinions and Dr. Mitchell's prosecution history estoppel opinions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development for Arbutus, as the core of its infringement claims against Moderna for the vast majority of vaccine sales remains in District Court, though the limitation on the doctrine of equivalents for some patents introduces a higher hurdle.

Positives

• The court largely denied Moderna's Section 1498(a) defense, allowing Arbutus's infringement claims for the vast majority of Moderna's COVID-19 vaccine doses (those sold to the general public) to remain in District Court.
• Arbutus can pursue indirect infringement claims even for vaccine doses distributed to government employees, as Section 1498(a) does not apply to indirect infringement.
• The court denied Moderna's summary judgment motions on patent indefiniteness for both the '651 Patent and the Molar Ratio Patents, meaning these validity challenges will proceed to a jury trial.

Negatives

• Arbutus is barred by prosecution history estoppel from asserting infringement claims under the doctrine of equivalents for its Molar Ratio Patents (U.S. Patent Nos. 8,492,359; 9,364,435; and 11,141,378), requiring proof of literal infringement.
• Direct infringement claims related to vaccine doses distributed directly to U.S. Government employees must be pursued in the Court of Federal Claims, rather than the District Court.
• The court granted Moderna's motion to exclude expert testimony from Alex Brill and Peter Pitts regarding the Section 1498(a) defense.

Risks

• Arbutus faces a higher burden of proof for its Molar Ratio Patents, needing to demonstrate literal infringement rather than infringement under the doctrine of equivalents.
• The validity of Arbutus's '651 Patent and Molar Ratio Patents remains uncertain and will be decided by a jury, posing a risk of invalidation.
• Splitting the direct infringement claims for government-employee doses to the Court of Federal Claims could complicate litigation strategy and increase legal costs.
• The outcome of the jury trial on patent validity and literal infringement is uncertain and could significantly impact the potential damages awarded.

Future Outlook

The litigation will proceed to a jury trial to resolve factual disputes regarding the validity (indefiniteness) of Arbutus's '651 Patent and Molar Ratio Patents. Arbutus will need to prove literal infringement for its Molar Ratio Patents, and the majority of its infringement claims against Moderna will continue in the District Court.

Industry Context

StockSavvy.ai notes that this ruling highlights the intense intellectual property landscape surrounding groundbreaking biotechnologies like mRNA vaccines and LNP delivery systems. The partial rejection of the government contractor defense (Section 1498) for the vast majority of vaccine sales sets a precedent that could impact future government-backed health initiatives and the patent protection afforded to innovators in such programs. The focus on literal infringement over the doctrine of equivalents for key patents underscores the importance of precise patent claim drafting and the challenges of enforcing broad patent rights in rapidly evolving fields.

Legal Proceedings

• U.S. District Court for the District of Delaware issued a memorandum and order in the patent infringement litigation (Case No. 1:22-cv-00252-JDW) filed by Arbutus Biopharma Corporation and Genevant Sciences GmbH against Moderna Inc. and ModernaTX, Inc.
• The litigation seeks damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of Moderna's COVID-19 vaccine (mRNA-1273).
• The court ruled that Moderna's Section 1498(a) defense applies only to direct infringement claims for vaccine doses distributed to U.S. Government employees, channeling these to the Court of Federal Claims.
• The court denied Moderna's Section 1498(a) defense for the vast majority of vaccine doses sold to the general public, allowing these claims to proceed in District Court.
• The court found that prosecution history estoppel bars Arbutus from asserting doctrine of equivalents claims for Molar Ratio Patents ('359, '435, '378), requiring literal infringement proof.
• Summary judgment motions on the indefiniteness of the '651 Patent and Molar Ratio Patents were denied, meaning these validity challenges will be decided by a jury.

Stakeholder Impact

• **Shareholders (Arbutus)**: The ruling allows the core of the patent infringement case to proceed in District Court, which could lead to significant damages if Arbutus prevails, potentially increasing shareholder value. However, the limitation on the doctrine of equivalents and the ongoing validity challenges introduce uncertainty.
• **Shareholders (Moderna)**: The ruling means Moderna still faces substantial patent infringement liability in District Court for the majority of its COVID-19 vaccine sales, which could negatively impact future earnings and shareholder value if Arbutus wins.
• **Biopharma Industry**: The case highlights the complexities of intellectual property rights in public health emergencies and government contracts, potentially influencing future R&D and licensing strategies for LNP and mRNA technologies.

Next Steps

• A jury trial will be held to resolve factual disputes regarding the validity (indefiniteness) of Arbutus's '651 Patent and Molar Ratio Patents.
• Arbutus will pursue literal infringement claims for its Molar Ratio Patents (U.S. Patent Nos. 8,492,359; 9,364,435; and 11,141,378) in District Court.
• Arbutus will continue to pursue infringement claims for the majority of Moderna's COVID-19 vaccine doses in the U.S. District Court for the District of Delaware.
• Direct infringement claims for vaccine doses distributed to U.S. Government employees will need to be pursued in the U.S. Court of Federal Claims.
• Arbutus can pursue indirect infringement claims for all vaccine doses in the District Court.

Key Dates

Recommendation

While Arbutus secured a favorable ruling allowing the majority of its patent infringement claims against Moderna to proceed in District Court, the limitation on the doctrine of equivalents for key patents and the ongoing uncertainty regarding patent validity (which will go to a jury) introduce significant risks. The potential for substantial damages is balanced by the litigation's complexity and uncertain outcome, warranting a 'hold' recommendation until further clarity emerges from the trial.

Keywords

Arbutus Biopharma, Moderna, Patent Infringement, mRNA Vaccine, COVID-19, LNP Technology, Lipid Nanoparticle, SEC Filing, 8-K, Delaware District Court, Section 1498, Prosecution History Estoppel, Doctrine of Equivalents, Patent Validity, Indefiniteness, Biotechnology, Pharmaceutical Litigation, Intellectual Property